Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group. Michot JM, et al. Among authors: sibon d. Am J Hematol. 2015 Mar;90(3):197-203. doi: 10.1002/ajh.23889. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25417909 Free article. Clinical Trial.
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma.
Romero M, Brière J, de Bazelaire C, Lebœuf C, Wang L, Ratajczak P, Sibon D, de Kerviler E, Thieblemont C, Janin A. Romero M, et al. Among authors: sibon d. Cancer Chemother Pharmacol. 2011 Nov;68(5):1135-43. doi: 10.1007/s00280-011-1589-9. Epub 2011 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 21380563
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Sibon D, Ertault M, Al Nawakil C, de Bazelaire C, Franchi P, Brière J, de Kerviler E, Beranger N, Thieblemont C, Brice P. Sibon D, et al. Br J Haematol. 2011 Apr;153(2):191-8. doi: 10.1111/j.1365-2141.2011.08594.x. Epub 2011 Mar 8. Br J Haematol. 2011. PMID: 21385169 Free article. Clinical Trial.
Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T, Suarez F, Marcais A, Sibon D, Buzyn A, Caillat-Zucman S, Cavazzana-Calvo M, Varet B, Dy M, Hermine O, Leite-de-Moraes M. Rubio MT, et al. Among authors: sibon d. Blood. 2012 Sep 6;120(10):2144-54. doi: 10.1182/blood-2012-01-404673. Epub 2012 Jun 22. Blood. 2012. PMID: 22730537 Free article.
Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases.
Resche-Rigon M, Pirracchio R, Robin M, De Latour RP, Sibon D, Ades L, Ribaud P, Fermand JP, Thieblemont C, Socié G, Chevret S. Resche-Rigon M, et al. Among authors: sibon d. BMC Blood Disord. 2012 Aug 16;12:10. doi: 10.1186/1471-2326-12-10. BMC Blood Disord. 2012. PMID: 22898556 Free PMC article.
Clinical trials of adult T-cell leukaemia/lymphoma treatment.
Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Marçais A, et al. Among authors: sibon d. Leuk Res Treatment. 2012;2012:932175. doi: 10.1155/2012/932175. Epub 2012 Feb 14. Leuk Res Treatment. 2012. PMID: 23213552 Free PMC article.
86 results